November 21, 2022
Alnylam Japan on November 18 launched Amvuttra (vutrisiran) in Japan for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis, also known as transthyretin-mediated familial amyloid polyneuropathy (TTR-FAP). The US firm already markets Onpattro (patisiran), a first-generation hATTR treatment, in Japan. While...read more